Ocugen, Inc, a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases as well as developing a COVID-19 vaccine, has appointed Michael Shine as Senior Vice President, Commercial.
Michael Shine is a pharmaceutical and biotechnology executive with nearly 35 years of industry experience. Over the course of his career, Mr. Shine has held leadership positions within large pharmaceutical companies, including Novapharm Therapeutics, Colgate Oral Pharmaceutical, and Pfizer Vaccines (formerly Wyeth). He also served as Chief Marketing Officer with Thomas Reuters and spent more than eight years in the start-up pharmaceutical space.
Shine led the successful commercial launch of the global $6bn Prevnar vaccine franchise while with Pfizer Vaccines (formerly Wyeth). He was also responsible for the development of innovative strategies for Prevenar’s inclusion in national immunization programs in key markets, driving sales in excess of $2bn.
Shine holds a Master of Business Administration from Villanova University, and a Bachelor of Science in business administration from the University of Scranton.